[1. D. Fleisher, C. Li, Y. Zhou, L. H. Pao and A. Karim, Drug, meal and formulation interactions influencing drug absorption after oral administration clinical implications, Clin. Pharmacokinet. 36 (1999) 233-254; DOI: 10.2165/00003088-199936030-00004.10.2165/00003088-199936030-00004]Search in Google Scholar
[2. K. A. Lentz, Current methods for predicting human food effect, The AAPS Journal 10 (2008) 282-288; DOI: 10.1208/s12248-008-9025-8.10.1208/s12248-008-9025-8]Search in Google Scholar
[3. FDA/CDER (2002), Guidance for Industry: Food-effect Bioavailability and Fed Bioequivalence Studies.]Search in Google Scholar
[4. EMA/CPMP (2010), Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **.]Search in Google Scholar
[5. EMA/CHMP (2014), Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms, EMA/CPMP/EWP/280/96 Corr1.]Search in Google Scholar
[6. W. Jiang, S. Kim, X. Zhang, R. A. Lionberger, B. M. Davit, D. P. Conner and L. X. Yu, The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation, Int. J. Pharm. 418 (2011) 151-160; DOI: 10.1016/j.ijpharm.2011.07.024.10.1016/j.ijpharm.2011.07.024]Search in Google Scholar
[7. E. S. Kostewicz, L. Aarons, M. Bergstrand, M. B. Bolger, A. Galetin, O. Hatley, M. Jamei, R. Lloyd, X. Pepin, A. Rostami-Hodjegan, E. Sjögren, C. Tannergren, D. B. Turner, C. Wagner, W. Weitschies and J. Dressman, PBPK models for the prediction of in vivo performance of oral dosage forms, Eur. J. Pharm. Sci. 57 (2014) 300-321; DOI: 10.1016/j.ejps.2013.09.008.10.1016/j.ejps.2013.09.008]Search in Google Scholar
[8. E. S. Kostewicz, B. Abrahamsson, M. Brewster, J. Brouwers, J. Butler, S. Carlert, P. A. Dickinson, J. Dressman, R. Holm, S. Klein, J. Mann, M. McAllister, M. Minekus, U. Muenster, A. Müllertz, M. Verwei, M. Vertzoni, W. Weitschies and P. Augustijns, In vitro models for the prediction of in vivo performance of oral dosage forms, Eur. J. Pharm. Sci. 57 (2014) 342-366; DOI: 10.1016/j. ejps.2013.08.024.]Search in Google Scholar
[9. EMA, QWP (2012), Guideline on Quality of Oral Modified Release Products, Draft, EMA/ 492713/2012.]Search in Google Scholar
[10. B. Abrahamsson, K. Roos and J. Sjogren, Investigation of prandial effects on hydrophilic matrix tablets, Drug Dev. Ind. Pharm. 25 (1999) 765-771; DOI: 10.1081/DDC-100102236.10.1081/DDC-100102236]Search in Google Scholar
[11. J. Parojčić, D. Vasiljević, S. Ibrić and Z. Đurić, Tablet disintegration and drug dissolution in viscous media: Paracetamol IR tablets, Int. J. Pharm. 355 (2008) 93-99; DOI: 10.1016/j.ijpharm.2007.11.058.10.1016/j.ijpharm.2007.11.058]Search in Google Scholar
[12. B. Abrahamsson, M. Alpsten, B. Bake, U. E. Jonsson, M. Eriksson-Lepkowska and A. Larsson, Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet - comparison with an osmotic pump tablet and effect of food, J. Control. Rel. 52 (1998) 301-310; DOI: 10.1016/ S0168-3659(97)00267-8.10.1016/S0168-3659(97)00267-8]Search in Google Scholar
[13. C. Wagner, K. Thelen, S. Willmann, A. Selen and J. B. Dressman, Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: Case example nifedipine immediate release formulation, J. Pharm. Sci. 102 (2013) 3205-3219; DOI: 10.1002/jps.23611.10.1002/jps.23611]Search in Google Scholar
[14. B. S. Schug, E. Brendel, D. Wolf, M. Wonnemann, M. Wargenau and H. H. Blume, Formulationdependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union, Eur. J. Pharm. Sci. 15 (2002) 279-285; DOI: 10.1016/S0928-0987(02)00008-8.10.1016/S0928-0987(02)00008-8]Search in Google Scholar
[15. M. Wonnemann, B. Schug, K. Schmücker, E. Brendel, P. A. van Zwieten and H. Blume, Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union, Int. J. Clin. Pharmacol. Ther. 44 (2006) 38-48; DOI: 10.5414/CPP44038.10.5414/CPP44038]Search in Google Scholar
[16. M. Wonnemann, B. S. Schug, M. Anschutz, E. Brendel, G. De Nucci and H. H. Blume, Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study, Clin. Ther. 30 (2008) 48-58; DOI: 10.1016/j.clinthera.2008.01.001.10.1016/j.clinthera.2008.01.001]Search in Google Scholar
[17. N. Patel, S. Polak, M. Jamei, A. Rostami Hodjegan and D. B. Turner, Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the phys iologically-based ADAM model: A case study using the BCS/BDDCS Class II drug nifedipine, Eur. J. Pharm. Sci. 57 (2014) 240-249; DOI: 10.1016/j.ejps.2013.09.006.10.1016/j.ejps.2013.09.006]Search in Google Scholar
[18. T. J. Rashid, U. Martin, H. Clarke, D. G. Waller, A. G. Renwick and C. F. George, Factors affecting the absolute bioavailability of nifedipine, Br. J. Clin. Pharmacol. 40 (1995) 51-58; DOI: 10.1111/ j.1365-2125.1995.tb04534.x.10.1111/j.1365-2125.1995.tb04534.x]Search in Google Scholar
[19. J. C. Loo and S. Riegelman, New method for calculating the intrinsic absorption rate of drugs, J. Pharm. Sci. 57 (1968) 918-928; DOI: 10.1002/jps.2600570602.10.1002/jps.2600570602]Search in Google Scholar
[20. B. Agoram, W. S. Woltosz and M. B. Bolger, Predicting the impact of physiological and biochemical processes on oral drug bioavailability, Adv. Drug Deliv. Rev. 50 (2001) S41-S67; DOI: 10.1016/ S0169-409X(01)00179-X.10.1016/S0169-409X(01)00179-X]Search in Google Scholar
[21. M. Ilić, J. Đuriš, I. Kovačević, S. Ibrić and J. Parojčić, In vitro - in silico - in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: Nifedipine osmotic release tablets case study, Eur. J. Pharm. Sci. 62 (2014) 212-218; DOI: 10.1016/j.ejps.2014.05.030.10.1016/j.ejps.2014.05.03024911992]Search in Google Scholar
[22. E. Jantratid, N. Janssen, C. Reppas and J. B. Dressman, Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update, Pharm. Res. 25 (2008) 1663-1676; DOI: 10.1007/s11095-008-9569-4.10.1007/s11095-008-9569-418404251]Search in Google Scholar
[23. Summary of Product Characteristics: Adalat modified release tablets, Bayer plc, revision date April 12, 2012 (www.medicines.org.uk).]Search in Google Scholar
[24. K. Hirasawa, W. F. Shen, D. T. Kelly, G. Roubin, K. Tateda and J. Shibata, Effect of food ingestion on nifedipine absorption and haemodynamic response, Eur. J. Clin. Pharmacol. 28 (1985) 105-107; DOI: 10.1007/BF00635716.10.1007/BF006357163987781]Search in Google Scholar
[25. V. Challenor, D. G. Waller, B. S. Gruchy, A. G. Renwick, C. F. George, E. T. McMurdo and J. McEwen, The effect of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine, Br. J. Clin. Pharmacol. 22 (1986) 565-570; DOI: 10.1111/j.1365-2125.1986.tb02936.x.10.1111/j.1365-2125.1986.tb02936.x14011743790403]Search in Google Scholar
[26. J. Armstrong, V. F. Challenor, B. S. Macklin, A. G. Renwick and D. G. Waller, The influence of two types of meal on the pharmacokinetics of a modified-release formulation of nifedipine (Adalat Retard), Eur. J. Clin. Pharmacol. 53 (1997) 141-143; DOI: 10.1007/s002280050352.10.1007/s0022800503529403286]Search in Google Scholar
[27. FDA/CDER (1998), Bioequivalence Review: Application Number 75-108.]Search in Google Scholar
[28. K. B. Nemes, V. Horvath, G. Grezal, G. Horvai, A. Hrabeczy-Pall, E. Kocsi, S. Drabant, M. Csorgo, G. Rencez and I. Klebovich, Food interaction pharmacokinetic study of Cordaflex 20 mg retard film tablet in healthy volunteers, Int. J. Clin. Pharmacol. Ther. 36 (1998) 263-269.]Search in Google Scholar
[29. B. S. Schug, E. Brendel, M. Wonnemann, D. Wolf, M. Wargenau, A. Dingler and H. H. Blume, Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast, Eur. J. Clin. Pharmacol. 58 (2002) 119-125; DOI: 10.1007/s00228-002-0444-7.10.1007/s00228-002-0444-712012144]Search in Google Scholar
[30. B. S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall and H. H. Blume, The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lagtime after a high fat breakfast, Br. J. Clin. Pharmacol. 53 (2002) 582-588; DOI: 10.1046/j.1365-2125. 2002.01599.x.]Search in Google Scholar
[31. J. M. Custodio, C. Y. Wu and L. Z. Benet, Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption, Adv. Drug Deliv. Rev. 60 (2008) 717-733; DOI: 10.1016/j.addr.2007.08.043.10.1016/j.addr.2007.08.043229281618199522]Search in Google Scholar
[32. S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, The AAPS Journal 12 (2010) 397-406; DOI: 10.1208/s12248-010-9203-3.10.1208/s12248-010-9203-3289543820458565]Search in Google Scholar
[33. C. Piovella, Clinical efficacy and bioavailability of a sustained release nifedipine formulation, Arzneimittelforschung 37 (1987) 832-835. ]Search in Google Scholar